Company News »

Genocea Named in Top Places to Work List by The Boston Globe

Business Wire
Share on StockTwits
Published on

Genocea Biosciences, Inc. (NASDAQ:GNCA) , a company developing T cell-directed vaccines and immunotherapies, today announced that it has been named as one of Boston’s Top Places to Work by The Boston Globe.

“We’re delighted to have been named to the Globe’s Top Places to Work list,” said Chip Clark, president and chief executive officer of Genocea. “As we pursue our mission to develop life-changing medicines, we will continue to build a culture where our employees are inspired, challenged and excited when they come to work each day. Genocea’s achievements to date are a testament to the dedication and successes of the people who work here.”

The Boston Globe honors Massachusetts’ best employers in its annual Top Places to Work magazine, which is online at www.BostonGlobe.com/topplaces and will appear in The Boston Sunday Globe on November 16.

About Genocea
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLASTM, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea’s pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy. For more information, visit www.genocea.com.

Share on StockTwits